Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 46 results.
User Information
Export Records
  1. 1.   Structural basis for complement receptor engagement and virus neutralization through Epstein-Barr virus gp350
  2. Joyce, M Gordon; Bu, Wei; Chen, Wei-Hung; Gillespie, Rebecca A; Andrews, Sarah F; Wheatley, Adam K; Tsybovsky,Yaroslav; Jensen, Jaime L; Stephens,Tyler; Prabhakaran, Madhu; Fisher, Brian E; Narpala, Sandeep R; Bagchi, Meghna; McDermott, Adrian B; Nabel, Gary J; Kwong, Peter D; Mascola, John R; Cohen, Jeffrey I; Kanekiyo, Masaru
  3. Immunity. 2025, Feb 11; 58(2): 295-308.e5. .
  1. 2.   Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase
  2. Lederhofer, Julia; Tsybovsky,Yaroslav; Nguyen, Lam; Raab, Julie E; Creanga, Adrian; Stephens,Tyler; Gillespie, Rebecca A; Syeda, Hubza Z; Fisher, Brian E; Skertic, Michelle; Yap, Christina; Schaub, Andrew J; Rawi, Reda; Kwong, Peter D; Graham, Barney S; McDermott, Adrian B; Andrews, Sarah F; King, Neil P; Kanekiyo, Masaru
  3. Immunity. 2024, Mar 12; 57(3): 574-586.e7.
  1. 3.   Distinct uptake and elimination profiles for trastuzumab, human IgG and biocytin-TMR in experimental HER2+ brain metastases of breast cancer
  2. Silvestri, Vanesa L; Tran, Andy D; Chung, Monika; Chung, Natalie; Gril, Brunilde; Robinson,Christina; Difilippantonio,Simone; Wei, Debbie; Kruhlak, Michael J; Peer, Cody J; Figg, W Douglas; Khan, Imran; Steeg, Patricia S
  3. Neuro-Oncology. 2024, Feb 13;
  1. 4.   Re-Engineering Therapeutic Anti-Aß Monoclonal Antibody to Target Amyloid Light Chain
  2. Bai, Jingyi; Li, Xi; Zhao, Jun; Zong, Huifang; Yuan, Yuan; Wang, Lei; Zhang, Xiaoshuai; Ke, Yong; Han, Lei; Xu, Jianrong; Ma, Buyong; Zhang, Baohong; Zhu, Jianwei
  3. International Journal of Molecular Sciences. 2024, Jan 27; 25(3):
  1. 5.   Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling
  2. Cecchi, Fabiola; Rex, Karen; Schmidt, Joanna; Vocke, Cathy D; Lee, Young H; Burkett, Sandra; Baker, Daniel; Damore, Michael A; Coxon, Angela; Burgess, Teresa L; Bottaro, Donald P
  3. Cancers. 2023, Jan 11; 15(2):
  1. 6.   A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusions
  2. Zhou, Ting; Yuan, Constance M; Lurain, Kathryn; Rous, Clarissa; Weaver, Linda; Raffeld, Mark; Stetler-Stevenson, Maryalice; Uldrick, Thomas S; Filie, Armando C; Pittaluga, Stefania; Jaffe, Elaine S; Marshall, Vickie; Moore,Kyle; Whitby,Denise; Ramaswami, Ramya; Yarchoan, Robert; Wang, Hao-Wei
  3. British Journal of Haematology. 2022, Oct 20;
  1. 7.   Quantitative PET imaging of the CD4 pool in nonhuman primates
  2. Kim,Insook; Srinivasula,Sharat; DeGrange, Paula; Long, Brad; Jang,Hyukjin; Carrasquillo, Jorge A; Lane, H Clifford; Di Mascio, Michele
  3. European Journal of Nuclear Medicine and Molecular Imaging. 2022, Aug 27;
  1. 8.   Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial
  2. Sasson, Jennifer; Donlan, Alexandra N; Ma, Jennie Z; Haughey, Heather M; Coleman, Rachael; Nayak, Uma; Mathers, Amy J; Laverdure,Sylvain; Dewar,Robin; Jackson, Patrick E H; Heysell, Scott K; Sturek, Jeffrey M; Petri, William A
  3. Open Forum Infectious Diseases. 2022, Aug; 9(8): ofac343.
  1. 9.   A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma
  2. Monge, Cecilia; Pehrsson,Erica; Xie, Changqing; Duffy, Austin G; Mabry, Donna; Wood, Bradford J; Kleiner, David E; Steinberg, Seth M; Figg, William D; Redd, Bernadette; Budhu, Anuradha; Wang, Sophie; Tandon,Mayank; Ma, Lichun; Wei Wang, Xin; Greten, Tim F
  3. The Oncologist. 2022, Mar 11; 27(3): e273-e285.
  1. 10.   IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses
  2. Harper, Taylor A.; Bacot, Silvia M.; Fennell, Christie Jane; Matthews,Rebecca; Zhu, Christina; Yue, Peng; Benton, Alexander; Friedman, Devira; Akue, Adovi; KuKuruga, Mark A.; Lee, Shiowjen; Wang, Tao; Feldman, Gerald M.
  3. International Journal of Molecular Sciences. 2021, Nov; 22(21):
  1. 11.   Controlled Organization of Inorganic Materials Using Biological Molecules for Activating Therapeutic Functionalities
  2. Chandler, Morgan; Minevich, Brian; Roark, Brandon; Viard,Mathias; Johnson, M Brittany; Rizvi, Mehedi H; Deaton, Thomas A; Kozlov, Seraphim; Panigaj, Martin; Tracy, Joseph B; Yingling, Yaroslava G; Gang, Oleg; Afonin, Kirill A
  3. ACS applied materials & interfaces. 2021, Aug 25; 13(33): 39030-39041.
  1. 12.   Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model
  2. El Meskini,Rajaa; Atkinson,Devon; Kulaga, Alan; Abdelmaksoud,Abdalla; Gumprecht, Michelle; Pate, Nathan; Hayes, Susana; Oberst, Michael; Kaplan, Ian M.; Raber, Patrick; Van Dyke, Terry; Sharan,Shyam; Hollingsworth, Robert; Day, Chi-Ping; Merlino, Glenn; Ohler,Zoe
  3. Molecular cancer research : MCR. 2021, Aug 1; 19(8): 1422-1436.
  1. 13.   A Randomized Double-Blinded, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
  2. Carter, Melody C; Maric, Irina; Brittain, Erica H; Bai, Yun; Lumbard,Keith; Bolan, Hyejeong; Cantave, Daly; Scott, Linda M; Metcalfe, Dean D
  3. The Journal of allergy and clinical immunology. 2021, Mar; 147(3): 1004-1010.e2.
  1. 14.   Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients
  2. Davar, Diwakar; Dzutsev, Amiran K.; McCulloch, John A.; Rodrigues,Richard; Chauvin, Joe-Marc; Morrison, Robert M.; Deblasio, Richelle N.; Menna, Carmine; Ding, Quanquan; Pagliano, Ornella; Zidi, Bochra; Zhang, Shuowen; Badger, Jonathan H.; Vetizou, Marie; Cole, Alicia M.; Fernandes, Miriam R.; Prescott, Stephanie; Costa, Raquel G. F.; Balaji, Ascharya K.; Morgun, Andrey; Vujkovic-Cvijin, Ivan; Wang, Hong; Borhani, Amir A.; Schwartz, Marc B.; Dubner, Howard M.; Ernst, Scarlett J.; Rose, Amy; Najjar, Yana G.; Belkaid, Yasmine; Kirkwood, John M.; Trinchieri,Giorgio; Zarour, Hassane M.
  3. Science. 2021, Feb 5; 371(6529): 595-602.
  1. 15.   Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers
  2. Zhao, Jun; Mohan, Nishant; Nussinov, Ruth; Ma, Buyong; Wu, Wen Jin
  3. Antibodies. 2021, Jan 12; 10(1):
  1. 16.   Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy
  2. Bacot, Silvia M.; Harper, Taylor A.; Matthews,Rebecca; Fennell, Christie Jane; Akue, Adovi; KuKuruga, Mark A.; Lee, Shiowjen; Wang, Tao; Feldman, Gerald M.
  3. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2020, DEC; 21(23):
  1. 17.   Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model
  2. Yamamoto, Jun; Miyake, Kentaro; Han, Qinghong; Tan, Yuying; Inubushi, Sachiko; Sugisawa, Norihiko; Higuchi, Takashi; Tashiro, Yoshihiko; Nishino, Hiroto; Homma, Yuki; Matsuyama, Ryusei; Chawla, Sant P; Bouvet, Michael; Singh,Shree Ram; Endo, Itaru; Hoffman, Robert M
  3. Cancer letters. 2020, NOV 1; 492: 174-184.
  1. 18.   Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model
  2. Philippou, Yiannis; Sjoberg, Hanna T.; Murphy, Emma; Alyacoubi, Said; Jones, Keaton I.; Gordon-Weeks, Alex N.; Phyu, Su; Parkes, Eileen E.; Gillies McKenna, W.; Lamb, Alastair D.; Gileadi, Uzi; Cerundolo, Vincenzo; Scheiblin,David; Lockett,Stephen; Wink,David; Mills, Ian G.; Hamdy, Freddie C.; Muschel, Ruth J.; Bryant, Richard J.
  3. BRITISH JOURNAL OF CANCER. 2020, JUL 9;
  1. 19.   Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease
  2. Ramaswami, Ramya; Lurain, Kathryn; Peer, Cody J.; Serquina, Anna; Wang, Victoria; Widell, Anaida; Goncalves, Priscila; Steinberg, Seth M.; Marshall,Vickie; George, Jomy; Figg, William D.; Whitby,Denise; Ziegelbauer, Joseph; Uldrick, Thomas S.; Yarchoan, Robert
  3. BLOOD. 2020, JUN 18; 135(25): 2316-2319.
  1. 20.   CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption
  2. Harper, Justin; Gordon, Shari; Chan, Chi Ngai; Wang, Hong; Lindemuth, Emily; Galardi, Cristin; Falcinelli, Shane D.; Raines, Samuel L. M.; Read, Jenna L.; Nguyen, Kevin; McGary, Colleen S.; Nekorchuk, Michael; Busman-Sahay, Kathleen; Schawalder, James; King, Colin; Pino, Maria; Micci, Luca; Cervasi, Barbara; Jean, Sherrie; Sanderson, Andrew; Johns, Brian; Koblansky, A. Alicia; Amrine-Madsen, Heather; Lifson,Jeffrey; Margolis, David M.; Silvestri, Guido; Bar, Katharine J.; Favre, David; Estes, Jacob D.; Paiardini, Mirko
  3. NATURE MEDICINE. 2020, Apr; 26(4): 519-528.
  1. 21.   Antibody-drug conjugates for cancer
  2. Chau, Cindy H.; Steeg,Pat; Figg, William D.
  3. Lancet (London, England). 2019, Aug 31; 394(10200): 793-804.
  1. 22.   Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model
  2. Higuchi, Takashi; Miyake, Kentaro; Sugisawa, Norihiko; Oshiro, Hiromichi; Zhang, Zhiying; Razmjooei, Sahar; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Bouvet, Michael; Singh, Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Cancer letters. 2019, Jun 1; 451: 122-127.
  1. 23.   The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model
  2. Higuchi, Takashi; Miyake, Kentaro; Sugisawa, Norihiko; Oshiro, Hiromichi; Zhang, Zhiying; Razmjooei, Sahar; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Bouvet, Michael; Singh,Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M.
  3. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2019, Jun; 83(6): 1075-1082.
  1. 24.   Report on the 2018 Cancer, Autoimmunity, and Immunology Conference
  2. Curran, Colleen S.; Sommers, Connie L.; Young,Howard; Bourcier, Katarzyna; Mancini, Marie; Sharon, Elad
  3. Journal of immunology (Baltimore, Md. : 1950). 2019, May 15; 202(10): 2823-2828.
  1. 25.   First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging
  2. Kurdziel, K A; Mena, E; McKinney, Y; Wong, K; Adler,Stephen; Sissung, T; Lee, J; Lipkowitz, S; Lindenberg, L; Turkbey, B; Kummar, S; Milenic, D E; Doroshow, J H; Figg, W D; Merino, M J; Paik, C H; Brechbiel, M W; Choyke, P L
  3. Journal of translational science. 2019, Apr; 5(2):
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel